×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABEO – abeona therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABEO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
07:57 am
abeo
Abeona Therapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Abeona Therapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
11/14
07:39 am
abeo
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
Low
Report
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates [Yahoo! Finance]
11/14
07:30 am
abeo
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Low
Report
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
11/13
12:08 am
abeo
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/12
01:56 pm
abeo
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment [Seeking Alpha]
Low
Report
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment [Seeking Alpha]
11/12
07:30 am
abeo
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
Medium
Report
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
11/7
02:07 pm
abeo
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio [Yahoo! Finance]
Low
Report
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio [Yahoo! Finance]
11/4
07:30 am
abeo
Abeona Therapeutics® Announces Participation in November Investor Conferences
Medium
Report
Abeona Therapeutics® Announces Participation in November Investor Conferences
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
09:59 am
abeo
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: JANUS HENDERSON GROUP PLC
11/14
07:31 am
abeo
Form 10-Q ABEONA THERAPEUTICS INC. For: Sep 30
Low
Report
Form 10-Q ABEONA THERAPEUTICS INC. For: Sep 30
11/14
07:30 am
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Nov 14
Low
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Nov 14
11/12
05:25 pm
abeo
Form DEF 14A ABEONA THERAPEUTICS INC. For: Nov 12
Low
Report
Form DEF 14A ABEONA THERAPEUTICS INC. For: Nov 12
11/12
09:44 am
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Nov 08
Medium
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Nov 08
10/29
07:31 am
abeo
Form 8-K ABEONA THERAPEUTICS INC. For: Oct 28
Low
Report
Form 8-K ABEONA THERAPEUTICS INC. For: Oct 28
10/17
04:31 pm
abeo
Form 4 ABEONA THERAPEUTICS INC. For: Oct 16 Filed by: Seshadri Vishwas
Low
Report
Form 4 ABEONA THERAPEUTICS INC. For: Oct 16 Filed by: Seshadri Vishwas
10/8
04:30 pm
abeo
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Low
Report
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/3
Abeona Therapeutics Announces Strategic Review
83.8%
3/16 Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates 40.7%
12/10 Abeona Therapeutics Inc (NASDAQ: ABEO) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $4.00 price target on the stock. 28.6%
10/15 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 21.0%
12/10 Form 8-K ABEONA THERAPEUTICS INC. For: Dec 09 20.7%
12/20 Form 25-NSE ABEONA THERAPEUTICS INC. Filed by: The Nasdaq Stock Market LLC 14.2%
2/10 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $6.00 price target on the stock. 11.4%
8/13 Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Royal Bank of Canada to $16.00. They now have a "positive" rating on the stock. 10.3%
2/11 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Leerink Swann. They set a "buy" rating and a $6.00 price target on the stock. 9.7%
1/21 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa 9.4%
3/16 Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates 40.7%
12/10 Abeona Therapeutics Inc (NASDAQ: ABEO) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $4.00 price target on the stock. 28.6%
10/15 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 21.0%
12/10 Form 8-K ABEONA THERAPEUTICS INC. For: Dec 09 20.7%
12/20 Form 25-NSE ABEONA THERAPEUTICS INC. Filed by: The Nasdaq Stock Market LLC 14.2%
2/10 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $6.00 price target on the stock. 11.4%
8/13 Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Royal Bank of Canada to $16.00. They now have a "positive" rating on the stock. 10.3%
2/11 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Leerink Swann. They set a "buy" rating and a $6.00 price target on the stock. 9.7%
1/21 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa 9.4%
TOP News Decliners
12/19
Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants
-37.7%
7/25 Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA -20.0%
6/18 Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease -16.5%
3/17 Form SEC STAFF LETTER ABEONA THERAPEUTICS INC. -15.4%
9/23 Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa -11.9%
8/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. -11.1%
12/9 Abeo on go with late-stage study of RDEB gene therapy; shares up 3% [Seeking Alpha] -10.4%
10/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.1%
1/13 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa -9.2%
12/4 Edited Transcript of ABEO earnings conference call or presentation 13-Nov-19 3:00pm GMT [Yahoo! Finance News] -8.6%
7/25 Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA -20.0%
6/18 Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease -16.5%
3/17 Form SEC STAFF LETTER ABEONA THERAPEUTICS INC. -15.4%
9/23 Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa -11.9%
8/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. -11.1%
12/9 Abeo on go with late-stage study of RDEB gene therapy; shares up 3% [Seeking Alpha] -10.4%
10/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.1%
1/13 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa -9.2%
12/4 Edited Transcript of ABEO earnings conference call or presentation 13-Nov-19 3:00pm GMT [Yahoo! Finance News] -8.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: